Navidea Biopharmaceuticals Inc (NAVB)

[LasNubes]

Not the case at all here.

You can get compassionate use especially when it is cheaper in the long run than the pathology bill for tedious lymph node mapping.

I think this will fly once it hits the market.

The medical-legal issues are addressed in the increased risk of radical lymph node dissection.

I can see doctors going straight to LS instead of putting patients through a much more radical surgery!

Keep in mind that they are considering stopping the randomization early because they don't feel that it is fair to the non-treatment arm cohort!

That says it all!!